Health News

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML)…

Read more

Filed under: Pharmacy News
Tags: Drug, leukemia, Oncology, Pharmacy

Related posts

• Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial (0)
  VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary [...]
  
  
• Vion Pharmaceuticals Announces Results Of The Oncologic Drugs Advisory Committee Meeting For Onrigin(TM) (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). [...]
  
  
• Sigma-Tau Pharmaceuticals Announces Approval For New Manufacturing Process For ONCASPAR® (Pegaspargase) Primary Ingredient (0)
  Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase). ONCASPAR is the only FDA-approved PEGylated formulation of L-asparaginase which is a key component in the treatment of acute lymphoblastic leukemia (ALL)... Read [...]
  
  
• Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010 (0)
  EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology [...]
  
  
• Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia (0)
  An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7. Read more [tags] Pharmacy [...]